1. Klein AP, Hruban RH, Brune KA, Petersen GM, Goggins M. Familial pancreatic cancer. Cancer J. 2001; 7:266–73.
2. MacDermott RP, Kramer P. Adenocarcinoma of the pancreas in four siblings. Gastroenterology. 1973; 65:137–9.
Article
3. Lynch HT, Deters CA, Lynch JF, Brand RE. Familial pancreatic carcinoma in Jews. Fam Cancer. 2004; 3:233–40.
Article
4. Gorski B, Cybulski C, Huzarski T, Byrski T, Gronwald J, Jakubowska A, et al. Breast cancer predisposing alleles in Poland. Breast Cancer Res Treat. 2005; 92:19–24.
Article
5. Cybulski C, Wokolorczyk D, Huzarski T, Byrski T, Gronwald J, Gorski B, et al. A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland. Breast Cancer Res Treat. 2007; 102:119–22.
6. Cybulski C, Kluzniak W, Huzarski T, Wokolorczyk D, Kashyap A, Jakubowska A, et al. Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. Lancet Oncol. 2015; 16:638–44.
Article
7. Menkiszak J, Gronwald J, Gorski B, Jakubowska A, Huzarski T, Byrski T, et al. Hereditary ovarian cancer in Poland. Int J Cancer. 2003; 106:942–5.
Article
8. Cybulski C, Gorski B, Huzarski T, Masojc B, Mierzejewski M, Debniak T, et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet. 2004; 75:1131–5.
Article
9. Cybulski C, Wokolorczyk D, Huzarski T, Byrski T, Gronwald J, Gorski B, et al. A large germline deletion in the CHEK2 kinase gene is associated with an increased risk of prostate cancer. J Med Genet. 2006; 43:863–6.
Article
10. Zlowocka E, Cybulski C, Gorski B, Debniak T, Slojewski M, Wokolorczyk D, et al. Germline mutations in the CHEK2 kinase gene are associated with an increased risk of bladder cancer. Int J Cancer. 2008; 122:583–6.
11. Teodorczyk U, Cybulski C, Wokolorczyk D, Jakubowska A, Starzynska T, Lawniczak M, et al. The risk of gastric cancer in carriers of CHEK2 mutations. Fam Cancer. 2013; 12:473–8.
Article
12. Cybulski C, Gorski B, Debniak T, Gliniewicz B, Mierzejewski M, Masojc B, et al. NBS1 is a prostate cancer susceptibility gene. Cancer Res. 2004; 64:1215–9.
Article
13. Lener MR, Scott RJ, Kluzniak W, Baszuk P, Cybulski C, Wiechowska-Kozlowska A, et al. Do founder mutations characteristic of some cancer sites also predispose to pancreatic cancer? Int J Cancer. 2016; 139:601–6.
Article
14. Slater EP, Langer P, Niemczyk E, Strauch K, Butler J, Habbe N, et al. PALB2 mutations in European familial pancreatic cancer families. Clin Genet. 2010; 78:490–4.
Article
15. Mocci E, Guillen-Ponce C, Earl J, Marquez M, Solera J, Salazar-Lopez MT, et al. PanGen-Fam: Spanish registry of hereditary pancreatic cancer. Eur J Cancer. 2015; 51:1911–7.
Article
16. Vasen H, Ibrahim I, Ponce CG, Slater EP, Matthai E, Carrato A, et al. Benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three European expert centers. J Clin Oncol. 2016; 34:2010–9.
Article
17. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature. 2000; 408:433–9.
Article
18. Matsuoka S, Huang M, Elledge SJ. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science. 1998; 282:1893–7.
Article
19. Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, Kilpivaara O, et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet. 2002; 71:432–8.
Article
20. Chehab NH, Malikzay A, Appel M, Halazonetis TD. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev. 2000; 14:278–88.
Article
21. Suchy J, Cybulski C, Wokolorczyk D, Oszurek O, Gorski B, Debniak T, et al. CHEK2 mutations and HNPCC-related colorectal cancer. Int J Cancer. 2010; 126:3005–9.
Article
22. Bartsch DK, Krysewski K, Sina-Frey M, Fendrich V, Rieder H, Langer P, et al. Low frequency of CHEK2 mutations in familial pancreatic cancer. Fam Cancer. 2006; 5:305–8.
Article